Australia’s Therapeutic Goods Administration (TGA) has approved the Breo Ellipta fluticasone furoate/vilanterol for the treatment of asthma and COPD, according to GSK Australia and Theravance.
GSK Medical Director Andrew Yeates commented, “We are delighted that Breo Ellipta is now approved in Australia. GSK is committed to supporting innovation in respiratory medicine and making medicines available to our Australian patients. Building on GSK’s strong respiratory heritage, we are proud that healthcare professionals in Australia have the option of prescribing this medicine when managing patients with asthma or COPD.”
According to the announcement, Breo Ellipta will not be available through Australia’s drug subsidy program, the Pharmaceutical Benefits Scheme (PBS).
Read the GSK/Theravance press release.
